Accepted Manuscript

Validation study of the Vitiligo Extent Score-plus (VESplus)

Nanja van Geel, MD, PhD, Albert Wolkerstorfer, MD, PhD, Janny E. Lommerts, MD, Khaled Ezzedine, MD, PhD, Viktoria Eleftheriadou, MD, PhD, Iltefat Hamzavi, MD, John Harris, MD, PhD, Mauro Picardo, MD, Alain Taieb, MD, PhD, Cecilia AC. Prinsen, MD, PhD, Marcel Bekkenk, MD, PhD, Reinhart Speeckaert, MD, PhD

PII: S0190-9622(17)32731-7

DOI: 10.1016/j.jaad.2017.11.032

Reference: YMJD 12136

To appear in: Journal of the American Academy of Dermatology

- Received Date: 25 September 2017
- Revised Date: 2 November 2017

Accepted Date: 12 November 2017

Please cite this article as: van Geel N, Wolkerstorfer A, Lommerts JE, Ezzedine K, Eleftheriadou V, Hamzavi I, Harris J, Picardo M, Taieb A, Prinsen CA, Bekkenk M, Speeckaert R, Validation study of the Vitiligo Extent Score-plus (VESplus), *Journal of the American Academy of Dermatology* (2017), doi: 10.1016/j.jaad.2017.11.032.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **RESEARCH LETTER**

2

3 Validation study of the Vitiligo Extent Score-plus (VESplus)

Nanja van Geel, MD, PhD¹, Albert Wolkerstorfer, MD, PhD², Janny E Lommerts, MD², Khaled
Ezzedine, MD, PhD³, Viktoria Eleftheriadou, MD, PhD⁴, Iltefat Hamzavi, MD⁵, John Harris,
MD, PhD⁶, Mauro Picardo, MD⁷, Alain Taieb, MD, PhD⁸, Cecilia AC Prinsen, MD, PhD⁹, Marcel
Bekkenk, MD, PhD², Reinhart Speeckaert, MD, PhD¹

8 ¹Department of Dermatology, Ghent University Hospital, Ghent, Belgium; ²Department of Dermatology, University of 9 Amsterdam and Netherlands Institute for Pigment Disorders, Amsterdam, The Netherlands; ³EA EpiDermE (Epidémiologie en 10 Dermatologie et Evaluation des Thérapeutiques), UPE-Université Paris-Est, Service de Dermatologie, Hôpital Henri Mondor, 11 Paris, France; ⁴Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, United Kingdom; 12 ⁵Department of Dermatology, Henry Ford Hospital, 3031 W Grand Blvd, Detroit, MI 48202, USA⁶Department of Medicine, 13 Division of Dermatology, University of Massachusetts Medical School, Worcester, MA, USA; ⁷San Gallicano Dermatology 14 Institute, Via Elio Chianesi, Roma, Italy; ⁸National Reference Center for rare skin diseases, Hôpital St-André, University 15 Hospital Center of Bordeaux, Bordeaux, France; ⁹VU University Medical Center, Department of Epidemiology and 16 Biostatistics, Amsterdam Public Health research institute, Amsterdam, The Netherlands.

17 18

19 **Corresponding author:**

- 20 Nanja van Geel, MD, PhD
- 21 Department of Dermatology, Ghent University Hospital
- 22 De Pintelaan 185, 9000 Ghent; Belgium
- 23 Tel: + 32-93322298; Fax: + 32-93324996; Nanja.vangeel@UGent.be
- 24 25

Statement funding sources: EADV grant (EADV Project proposal reference number 2015-030) and Leo Foundation grant (Leo Foundation project reference number LF16092). The research activities of the principle investigator N. van Geel are supported by the Scientific Research Foundation-Flanders (FWO Senior Clinical Investigator: 1831512N) and of R. Speeckaert by postdoctoral research grant (01P12914) from the Ghent University Special Research Fund.

31

Download English Version:

https://daneshyari.com/en/article/8715095

Download Persian Version:

https://daneshyari.com/article/8715095

Daneshyari.com